These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
51. Early treatment of Parkinson's disease. Open studies are unreliable. Myllylä V; Heinonen E BMJ; 1994 Jan; 308(6923):272-3. PubMed ID: 8111278 [No Abstract] [Full Text] [Related]
52. Late-stage Parkinson's disease in the Lisbon-Barcelona cohorts: past phenomenology and today's clinical needs. Echebarria SG J Neurol; 2011 May; 258(5):918-9; author reply 920. PubMed ID: 21082323 [No Abstract] [Full Text] [Related]
53. Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease. Okun MS; Lang A; Jankovic J Mov Disord; 2010 May; 25(7):961-2; author reply 962-3. PubMed ID: 20461816 [No Abstract] [Full Text] [Related]
58. Patients sought for New Zealand multi-centre Parkinson's disease trial. Wallis WE N Z Med J; 1987 Jan; 100(816):33. PubMed ID: 3543760 [No Abstract] [Full Text] [Related]
59. A progress report on the New Zealand Multicentre Parkinson's disease trial. A comparison of low-dose treatment with bromocriptine or L-dopa. Wallis WE Eur Neurol; 1988; 28 Suppl 1():9-10. PubMed ID: 3288479 [TBL] [Abstract][Full Text] [Related]
60. Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Factor SA; Weiner WJ Mov Disord; 1993 Jul; 8(3):257-62. PubMed ID: 8341289 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]